India’s Healthcare Business Daily
The partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries
Cipla announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension, 0.05 per cent (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, South Africa, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, Argentina, and Colombia.
APP13007 is a novel, patent protected and USFDA-approved ophthalmic product. It offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain. This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits.
Achin Gupta, Global COO, Cipla said, “The partnership with Formosa Pharmaceuticals marks a significant milestone for Cipla, as it is our first multi-regional licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio. We look forward to leveraging Cipla’s strong commercial presence to make a meaningful impact in post-operative eye care.”
“Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of innovative medicines and look forward to working together to provide our novel therapy to ocular surgery patients to their audience,” said Erick Co, President and CEO, Formosa Pharmaceuticals.
Join 15,000+ hospital leaders, founders and investors reading IndiaMedToday each morning.
The Company delivered a robust performance in Q2FY27, with consolidated revenue of ₹270.8 crore, up 25.1% year-on-year, led…
SCHOTT Poonawalla Private Limited Becomes SCHOTT Pharma India Private Limited Effective 28 October 2026, SCHOTT Poonawalla Private Limited…
The Hospital Energy Analysis Tool (HEAT) helps architects and healthcare planners assess energy requirements and explore cost-saving design…
India’s leading digital publication providing comprehensive reporting, business analysis, clinical technology insights, and leadership perspectives for healthcare professionals.
© 2026 IndiaMedToday . All rights reserved.
Loading comments…